Fulgent Genetics (FLGT) Set to Announce Quarterly Earnings on Thursday

Fulgent Genetics (NASDAQ:FLGT) is anticipated to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.65) per share and revenue of $86.30 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Fulgent Genetics Stock Up 0.6%

FLGT traded up $0.12 on Tuesday, hitting $19.41. The company’s stock had a trading volume of 26,385 shares, compared to its average volume of 403,153. The company’s 50 day simple moving average is $20.76 and its 200-day simple moving average is $19.46. The firm has a market cap of $533.97 million, a P/E ratio of -6.85 and a beta of 0.93. Fulgent Genetics has a 12 month low of $13.46 and a 12 month high of $31.04.

Analysts Set New Price Targets

FLGT has been the subject of several recent research reports. Piper Sandler lifted their price target on Fulgent Genetics from $15.00 to $19.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. Weiss Ratings raised Fulgent Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. Finally, Wall Street Zen upgraded Fulgent Genetics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $27.50.

Insider Buying and Selling at Fulgent Genetics

In related news, COO Jian Xie sold 2,127 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $19.66, for a total value of $41,816.82. Following the transaction, the chief operating officer owned 359,924 shares of the company’s stock, valued at $7,076,105.84. This represents a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Hanlin Gao sold 1,673 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $19.66, for a total value of $32,891.18. Following the sale, the insider owned 986,117 shares in the company, valued at $19,387,060.22. The trade was a 0.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,932 shares of company stock valued at $117,156 over the last quarter. 36.18% of the stock is owned by company insiders.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc is a technology-driven clinical diagnostics company that develops and performs genetic testing. Its testing platform uses next-generation sequencing and other molecular technologies to analyze DNA and support the diagnosis, screening and management of inherited and acquired diseases.

The company offers a range of tests, including panels for hereditary cancer, reproductive health and inherited disorders, as well as tumor profiling and other specialized clinical testing services.